Results 1 to 10 of about 1,174 (116)
Convalescent plasma therapy in patients with COVID-19 [PDF]
Transfusion and Apheresis Science, 2021 Passive antibody therapy has been used to immunize vulnerable people against infectious agents. In this study, we aim to investigate the efficacy of convalescent plasma (CP) in the treatment of severe and critically ill patients diagnosed with COVID-19.The data of severe or critically ill COVID-19 patients who received anti-SARS-CoV-2 antibody ...
Burhan Turgut +2 more
exaly +9 more sources
Convalescent COVID-19 plasma [PDF]
Scripta Medica, 2021 Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a new human disease. December 31, 2019 marked the day the World Health Organization (WHO) first became aware of an infectious outbreak in the ...
Vavić Nataša +2 more
doaj +2 more sources
Safety of Convalescent Plasma Transfusion [PDF]
Mayo Clinic Proceedings, 2021 n ...
Franchini, Massimo, Glingani, Claudia
openaire +2 more sources
Earlier the better: convalescent plasma [PDF]
Blood, 2020 In the current issue of Blood, Xia et al evaluate the use of convalescent plasma for the treatment of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19).(1,2) SARS-CoV-2 has spurred a global crisis.
Aaron A. R. Tobian, Beth H. Shaz
openaire +2 more sources
Donor tolerability of convalescent plasma donation [PDF]
Journal of Clinical Apheresis, 2021 AbstractBackgroundSince early 2020, convalescent plasma has been widely used for treating coronavirus disease 2019 (COVID‐19). There is limited information regarding donor tolerability of convalescent plasma donation. In this study, we evaluated the short‐term donor tolerability of convalescent plasma donation.MethodsA prospective study of 309 ...
He, Rui +11 more
openaire +2 more sources
Life, 2022 Background: Coronavirus disease 2019 is a global public health concern. As of December 2020, the therapeutic agents approved for coronavirus disease 2019 in Japan were limited to two drugs: remdesivir, an antiviral drug, granted a Special Approval for ...
Noriko Tomita +20 more
doaj +1 more source
Convalescent plasma for covid-19 [PDF]
BMJ, 2020 Authorisation in the US was premature, and a missed opportunity Plasma from people recovering from infection, particularly after severe illness, may contain high levels of polyclonal, pathogen specific antibodies. These antibodies may confer passive immunity to recipients, and in viral diseases are thought to act mainly by neutralising viral particles ...
Estcourt, Lise J, Roberts, David J
openaire +2 more sources
Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence
Frontiers in Medicine, 2021 Convalescent plasma has been used worldwide to treat patients hospitalized with coronavirus disease 2019 (COVID-19) and prevent disease progression. Despite global usage, uncertainty remains regarding plasma efficacy, as randomized controlled trials ...
Stephen A. Klassen +17 more
doaj +1 more source
Coagulation profile of human COVID-19 convalescent plasma
Scientific Reports, 2022 Convalescent plasma is used to treat COVID-19. There are theoretical concerns about the impact of pro-coagulant factors in convalescent plasma on the coagulation cascade particularly among patients with severe COVID-19.
Allan M. Klompas +13 more
doaj +1 more source
Response to convalescent plasma is not influenced by patient blood type
Global Journal of Transfusion Medicine, 2021 Background: SARS-CoV2 virus is associated with 580,000 deaths and 32.5 million cases of COVID-19 infection in the United States. Data exist suggesting a correlation between blood type and disease acquisition and severity. No such data exist between blood
William R Hartman +2 more
doaj +1 more source